Imetelstat leads to durable red blood cell transfusion independence
For heavily transfused patients with lower-risk myelodysplastic syndromes (LR-MDS) who are not responding to or are ineligible for erythropoiesis-stimulating agents (ESAs), the competitive telomerase inhibitor imetelstat ...
Jan 9, 2024
0
0